1-to-1 Media PitchingGive us two hours and we'll get your covered. With the volume of press releases sent daily, it sometimes takes more than an email or wire release to attract the attention of a busy reporter. In many cases, reporters need stories tailored to the needs of a specific section or feature that's run on a regular basis. In this case, a simple Q & A sent to a journalist may be more effective than a press release. We understand that our clients are not always eager to pick up the phone and call a reporter directly. So we'll do it for you. Xpress Press can work with you on an hourly basis ($75 per hour/$150 minimum) to help maximize your story's impact. It can take as little as 15 minutes, or up to several hours to work with individual reporters or producers depending on their information requirements. For budgeting purposes, we suggest that our clients allocate one hour per media outlet contacted as a starting point. Call our office at 954-989-3338 for a quick review of how 1-to-1 Media Pitching might benefit your company.
ATLANTA – December 14 – Micron Optics, Inc., the leading provider of innovative equipment for fiber optic sensing, today announces the new os3500 Optical Strain Sensor. This new rugged, optical strain sensor represents the latest in Fiber Bragg grating (FBG) sensor technology and is optimized exclusively for embedded applications.
The os360, released in 2004, was the first [...]
Over the past decade, the prevalence of cirrhosis has increased by almost 40 percent among people with hepatitis C (HCV) in the United States, according to research presented at The Liver Meeting® — held by the American Association for the Study of Liver Diseases.
The use of statins has been shown to significantly decrease risk of death among patients with alcoholic cirrhosis, according to research p
The prevalence of nonalcoholic steatohepatitis (NASH), a progressive type of fatty liver disease, appears to be on the rise in adolescents, increasing four-fold between 1988 and 2010, according to research presented this week at The Liver Meeting® — held by the American Association for the Study of Liver Diseases.
A new study presented this week at The Liver Meeting® — held by the American Association for the Study of Liver Diseases — found patients with hepatitis C who take direct-acting antiviral medication are at no higher risk for developing liver cancer than those who do not take the medication.